NCT05410418View on ClinicalTrials.gov

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2031

Conditions
Lymphoma, FollicularFollicular Lymphoma
Interventions
DRUG

Mosunetuzumab

"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."

DRUG

Polatuzumab vedotin

Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Institute for Follicular Lymphoma

UNKNOWN

lead

Washington University School of Medicine

OTHER